Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Halimi, Jean-Michel
• dc.contributor.author Oliveras, Anna
• dc.contributor.author Vogt, Liffert
• dc.date.accessioned 2025-03-06T07:22:27Z
• dc.date.available 2025-03-06T07:22:27Z
• dc.date.issued 2024
• dc.description.abstract Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70-95%]) than MRA (20% [10-30%]), SGLT2i (30% [20-50%]) or (GLP1-RA (10% [5-15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15-40%) vs 18% [10%-25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5-5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management.
• dc.format.mimetype application/pdf
• dc.identifier.citation Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, et al. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney. Blood Press. 2024 Dec;33(1):2368800. DOI: 10.1080/08037051.2024.2368800
• dc.identifier.doi http://dx.doi.org/10.1080/08037051.2024.2368800
• dc.identifier.issn 0803-7051
• dc.identifier.uri http://hdl.handle.net/10230/69833
• dc.language.iso eng
• dc.publisher Taylor & Francis
• dc.relation.ispartof Blood Press. 2024 Dec;33(1):2368800
• dc.rights © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Chronic kidney disease
• dc.subject.keyword RAS blockers
• dc.subject.keyword SGLT2 inhibitors
• dc.subject.keyword Guidelines
• dc.subject.keyword Hyperkalaemia
• dc.subject.keyword Hypertension
• dc.subject.keyword Management
• dc.subject.keyword Mineralocorticoid receptor antagonists
• dc.title Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion